Edition:
United Kingdom

BeiGene Ltd (BGNE.OQ)

BGNE.OQ on NASDAQ Stock Exchange Global Select Market

149.92USD
21 Feb 2018
Change (% chg)

$14.26 (+10.51%)
Prev Close
$135.66
Open
$137.15
Day's High
$150.97
Day's Low
$137.15
Volume
136,604
Avg. Vol
123,710
52-wk High
$150.97
52-wk Low
$34.58

Chart for

About

BeiGene, Ltd. is a clinical-stage biopharmaceutical company. The Company is focused in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company had used its cancer biology platform to develop four clinical-stage drug candidates, such as BGB-3111, BGB-A317, BGB-290... (more)

Overall

Beta: --
Market Cap(Mil.): $4,400.80
Shares Outstanding(Mil.): 3.26
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 83.93 16.60
EPS (TTM): -- -- --
ROI: -- 1.66 10.66
ROE: -- 2.58 14.30

BRIEF-Wellington Management Group Llp Reports 8.39 pct Passive Stake In Beigene Ltd As Of Dec, 29, 2017

* WELLINGTON MANAGEMENT GROUP LLP REPORTS 8.39 PERCENT PASSIVE STAKE IN BEIGENE LTD AS OF DECEMBER 29, 2017 - SEC FILING‍​ Source text - (http://bit.ly/2EqL8XD) Further company coverage:

08 Feb 2018

BRIEF-BeiGene Announces Commercial Availability Of Vidaza In China

* BEIGENE ANNOUNCES COMMERCIAL AVAILABILITY OF VIDAZA® (AZACITIDINE FOR INJECTION) IN CHINA

05 Feb 2018

BRIEF-BeiGene Initiates Global Phase 3 Trial Of Anti-PD-1 Antibody Tislelizumab

* BEIGENE INITIATES GLOBAL PHASE 3 TRIAL OF ANTI-PD-1 ANTIBODY TISLELIZUMAB IN PATIENTS WITH ESOPHAGEAL SQUAMOUS CELL CARCINOMA Source text for Eikon: Further company coverage:

31 Jan 2018

BRIEF-BeiGene prices follow-on offering of 7.4 mln American depositary shares at $101 per ADS

* ‍PRICING OF FOLLOW-ON PUBLIC OFFERING OF 7. 4 MILLION AMERICAN DEPOSITARY SHARES AT A PRICE TO PUBLIC OF $101.00 PER ADS​ Source text for Eikon: Further company coverage:

18 Jan 2018

BRIEF-Beigene Announces Proposed Public Offering

* BEIGENE LTD - ‍PUBLIC OFFERING OF ITS AMERICAN DEPOSITARY SHARES (ADSS), EACH REPRESENTING 13 OF ITS ORDINARY SHARES, PAR VALUE $0.0001 PER SHARE​

16 Jan 2018

BRIEF-Beigene And Boehringer Ingelheim Announce Commercial Supply Agreement For Tislelizumab

* BEIGENE AND BOEHRINGER INGELHEIM ANNOUNCE COMMERCIAL SUPPLY AGREEMENT FOR ANTI-PD-1 ANTIBODY TISLELIZUMAB

09 Jan 2018

BRIEF-Beigene And Mirati Therapeutics Announce Exclusive License Agreement For Sitravatinib In The Asia Pacific Region

* BEIGENE AND MIRATI THERAPEUTICS ANNOUNCE EXCLUSIVE LICENSE AGREEMENT FOR SITRAVATINIB IN THE ASIA PACIFIC REGION

08 Jan 2018

BRIEF-Beigene Initiates Global Phase 3 Trial Of Anti-PD-1 Antibody Tislelizumab In Patients With Hepatocellular Carcinoma

* BEIGENE INITIATES GLOBAL PHASE 3 TRIAL OF ANTI-PD-1 ANTIBODY TISLELIZUMAB IN PATIENTS WITH HEPATOCELLULAR CARCINOMA Source text for Eikon: Further company coverage:

02 Jan 2018

BRIEF-BeiGene Initiates Pivotal Trial Of PARP Inhibitor Pamiparib In China

* BEIGENE INITIATES PIVOTAL TRIAL OF PARP INHIBITOR PAMIPARIB (BGB-290) IN CHINA IN PATIENTS WITH OVARIAN CANCER Source text for Eikon: Further company coverage:

18 Dec 2017

BRIEF-Beigene expands global pivotal program for BTK inhibitor BGB-3111

* Beigene expands global pivotal program for BTK inhibitor BGB-3111

13 Nov 2017

Earnings vs. Estimates